drugset / Trial / NCT00767624

TRIAD - Treatment of Insomnia and Depression

NCT00767624 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.

Timeline

Start
2008-12
Primary completion
2015-06
Completion
2015-06

Outcome

Mixed primary results

paper CBT-I was superior to CTRL in reducing insomnia severity (P = .028). PMID 27788313 ↗

paper The overall difference in depression remission between the treatments was not statistically significant (44% in CBT-I and 36% in CTRL; number needed to treat = 15). PMID 27788313 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified — —
Subject Escitalopram Small molecule — —
Subject Sertraline Small molecule — —